Valuation: Halozyme Therapeutics, Inc.

Market Cap 11.55B 10.01B 9.38B 8.55B 16.08B 1,102B 16.33B 110B 43.12B 552B 43.38B 42.43B 1,840B P/E 2026 *
14.1x
P/E 2027 * 11.4x
Enterprise Value 12.9B 11.17B 10.47B 9.55B 17.95B 1,230B 18.23B 123B 48.13B 616B 48.42B 47.37B 2,054B EV / Sales 2026 *
6.96x
EV / Sales 2027 * 5.79x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week+21.77%
Current month+23.32%
1 month+33.58%
3 months+43.51%
6 months+32.33%
Current year+51.25%
1 week 90
Extreme 90
104.78
1 month 73.89
Extreme 73.8901
104.78
Current year 61.32
Extreme 61.325
104.78
1 year 61.22
Extreme 61.225
104.78
3 years 32.83
Extreme 32.83
104.78
5 years 29.85
Extreme 29.85
104.78
10 years 8.18
Extreme 8.18
104.78
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Chief Executive Officer

5,769 0.0049%
7/1/26 Free

Executive/Senior Manager

56,055 0.0473%
7/1/26 Free

Chief Financial Officer

168,986 0.1425%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%+21.77%+58.95%+132.66% 11.55B
+1.92%+3.58%+65.53%+23.72% 328B
+0.02%-3.31%+26.38%-13.66% 70.25B
+0.79%+3.92%-0.70%-2.17% 8.52B
-2.54%+7.56%-10.73%-6.86% 4.88B
-2.92%+10.65%-25.14%+15.26% 4.37B
-0.76%+13.44%+2.89%+48.08% 4.22B
+2.11%+2.05%+16.08%+50.11% 2.78B
-2.00%-0.14%-1.79%-1.14% 2.24B
+0.03%+12.03%-14.89%+47.52% 2.01B
Average -0.42%+6.84%+11.66%+29.35% 43.88B
Weighted average by Cap. +1.37%+3.12%+54.42%+20.06%

Financials

2026 *2027 *
Net sales 1.85B 1.61B 1.5B 1.37B 2.58B 177B 2.62B 17.7B 6.92B 88.53B 6.96B 6.81B 295B 2.05B 1.78B 1.66B 1.52B 2.85B 196B 2.9B 19.58B 7.65B 97.93B 7.7B 7.53B 327B
Net income 869M 753M 705M 643M 1.21B 82.86B 1.23B 8.29B 3.24B 41.49B 3.26B 3.19B 138B 1.07B 925M 867M 791M 1.49B 102B 1.51B 10.2B 3.99B 51B 4.01B 3.92B 170B
Net Debt 1.34B 1.16B 1.09B 995M 1.87B 128B 1.9B 12.83B 5.02B 64.18B 5.05B 4.94B 214B 320M 277M 259M 237M 445M 30.47B 452M 3.05B 1.19B 15.26B 1.2B 1.17B 50.88B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-08-12 US$101.79 -0.81% 3,650,585
26-08-11 US$102.62 0.00% 2,846,031
26-08-10 US$102.62 -0.48% 4,934,990
26-08-07 US$103.12 +20.24% 7,691,625
26-08-06 US$85.76 +2.60% 2,704,018
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
101.79USD
Average target price
99.56USD
Spread / Average Target
-2.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock